Breakthrough for mosquito virus outbreaks
Posted: 29 August 2017 | Dr Zara Kassam (Drug Target Review) | No comments yet
A team of researchers are developing ways to treat debilitating diseases caused by alphaviruses such as Chikungunya and Ross River virus…
A team of researchers are developing ways to treat debilitating diseases caused by alphaviruses such as Chikungunya and Ross River virus, the researchers have discovered a way that could help treat severe inflammation from an infectious mosquito-borne disease during outbreaks.
“When we infected mice with Chikungunya, we found that a type of inflammasome known as NLRP3 was activated, which triggered an inflammatory cascade, leading to severe joint inflammation and bone damage,” said Dr Ali Zaid, a lead author of the study.
“So we used a molecule which specifically inhibits the activation of NLRP3, and we found that it helped reduce Chikungunya inflammation in mice, and also helped reduce bone loss and muscle inflammation. “We found the same in mice infected with Ross River virus.
Targeting the inflammasome using this kind of drug could be an efficient way to treat patients suffering from acute Chikungunya or Ross River virus disease during outbreaks,” Dr Zaid added.
Collaborator Professor Matt Cooper from the Institute of Molecular Bioscience at the University of Queensland said, “By precisely modulating how our immune system responds to infection, we hope to develop new therapies that can be used to treat people with these serious diseases”
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
Professor Suresh Mahalingam said the findings were important as inflammasome NLRP3 was prominently expressed in CHIKV patients with severe disease. “The NLRP3 inhibitor drug, MCC950, provided significant amelioration of inflammation and disease in CHIKV-infected mice. The drug provided these therapeutic benefits without compromising antiviral immunity.”
The research has been published in the journal Nature Microbiology.
Related topics
Drug Targets, Therapeutics
Related conditions
Chikungunya, Ross River virus
Related organisations
Institute of Molecular Bioscience at the University of Queensland
Related people
Dr Ali Zaid, Professor Mahalingam, Professor Matt Cooper
